Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi

Francesco Zaja; Simone Ferrero; Caterina Stelitano; Angela Ferrari; Flavia Salvi; Annalisa Arcari; Gerardo Musuraca; Barbara Botto; Michele Spina; Claudia Cellini; Caterina Patti; Anna M Liberati; Claudia Minotto; Stefano A Pileri; Manuela Ceccarelli; Stefano Volpetti; Antonella Ferranti; Daniela Drandi; Elisa Montechiarello; Marco Ladetto; James Carmichael; Renato Fanin

doi:10.3324/haematol.2016.154211

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi

Francesco Zaja, Simone Ferrero, Caterina Stelitano, Angela Ferrari, Flavia Salvi, Annalisa Arcari, Gerardo Musuraca, Barbara Botto, Michele Spina, Claudia Cellini, Caterina Patti, Anna M Liberati, Claudia Minotto, Stefano A Pileri, Manuela Ceccarelli, Stefano Volpetti, Antonella Ferranti, Daniela Drandi, Elisa Montechiarello, Marco LadettoJames Carmichael, Renato Fanin

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e203-e206
Journal	Haematologica
Volume	102
Issue number	5
DOIs	https://doi.org/10.3324/haematol.2016.154211
Publication status	Published - May 2017

Keywords

Letter

Access to Document

10.3324/haematol.2016.154211

Cite this

Zaja, F., Ferrero, S., Stelitano, C., Ferrari, A., Salvi, F., Arcari, A., Musuraca, G., Botto, B., Spina, M., Cellini, C., Patti, C., Liberati, A. M., Minotto, C., Pileri, S. A., Ceccarelli, M., Volpetti, S., Ferranti, A., Drandi, D., Montechiarello, E., ... Fanin, R. (2017). Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica, 102(5), e203-e206. https://doi.org/10.3324/haematol.2016.154211

Zaja, F, Ferrero, S, Stelitano, C, Ferrari, A, Salvi, F, Arcari, A, Musuraca, G, Botto, B, Spina, M, Cellini, C, Patti, C, Liberati, AM, Minotto, C, Pileri, SA, Ceccarelli, M, Volpetti, S, Ferranti, A, Drandi, D, Montechiarello, E, Ladetto, M, Carmichael, J & Fanin, R 2017, 'Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi', Haematologica, vol. 102, no. 5, pp. e203-e206. https://doi.org/10.3324/haematol.2016.154211

@article{4be4abec210e42e6827909e8352d8702,

title = "Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi",

keywords = "Letter",

author = "Francesco Zaja and Simone Ferrero and Caterina Stelitano and Angela Ferrari and Flavia Salvi and Annalisa Arcari and Gerardo Musuraca and Barbara Botto and Michele Spina and Claudia Cellini and Caterina Patti and Liberati, {Anna M} and Claudia Minotto and Pileri, {Stefano A} and Manuela Ceccarelli and Stefano Volpetti and Antonella Ferranti and Daniela Drandi and Elisa Montechiarello and Marco Ladetto and James Carmichael and Renato Fanin",

year = "2017",

month = may,

doi = "10.3324/haematol.2016.154211",

language = "English",

volume = "102",

pages = "e203--e206",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "5",

}

TY - JOUR

T1 - Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma

T2 - a phase II clinical trial of the Fondazione Italiana Linfomi

AU - Zaja, Francesco

AU - Ferrero, Simone

AU - Stelitano, Caterina

AU - Ferrari, Angela

AU - Salvi, Flavia

AU - Arcari, Annalisa

AU - Musuraca, Gerardo

AU - Botto, Barbara

AU - Spina, Michele

AU - Cellini, Claudia

AU - Patti, Caterina

AU - Liberati, Anna M

AU - Minotto, Claudia

AU - Pileri, Stefano A

AU - Ceccarelli, Manuela

AU - Volpetti, Stefano

AU - Ferranti, Antonella

AU - Drandi, Daniela

AU - Montechiarello, Elisa

AU - Ladetto, Marco

AU - Carmichael, James

AU - Fanin, Renato

PY - 2017/5

Y1 - 2017/5

KW - Letter

U2 - 10.3324/haematol.2016.154211

DO - 10.3324/haematol.2016.154211

M3 - Article

C2 - 28082342

VL - 102

SP - e203-e206

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -